OpenAI Researcher Miles Wang to Launch AI Drug Discovery Startup Valued at $2 Billion

Washington DC, United States Jul 15, 2026 ALN: Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery. This experience will likely serve him well as he transitions to the startup world, where the application of AI in drug discovery is gaining momentum.

The intersection of artificial intelligence and drug discovery is a rapidly evolving field with significant implications for the pharmaceutical industry and healthcare at large. Traditionally, drug discovery has been a lengthy and costly process, often taking over a decade and billions of dollars to bring a new drug to market. By leveraging AI, researchers aim to streamline this process, reduce costs, and improve the success rates of drug candidates.

AI technologies can analyze vast datasets, including genetic information, clinical trial outcomes, and chemical properties, to identify potential drug candidates more efficiently than traditional methods. This capability is particularly valuable in the context of precision medicine, where treatments can be tailored to individual patients based on their unique genetic makeup.

Wang's focus on finding new uses for existing drugs is particularly noteworthy. The repurposing of drugs has gained traction in recent years, especially during the COVID-19 pandemic, where existing medications were quickly evaluated for their potential to treat the virus. The ability to swiftly identify new applications for already-approved drugs can not only save time but also significantly reduce the financial risks associated with drug development.

Investors have taken notice of this trend, as evidenced by the recent funding rounds for companies like Chai Discovery and Isomorphic Labs. These firms are at the forefront of integrating AI into the drug discovery process, and their substantial valuations reflect a growing confidence in the potential of AI-driven approaches to revolutionize the industry.

The competitive landscape in AI drug discovery is becoming increasingly crowded, with numerous startups and established companies vying for dominance. This environment fosters innovation but also raises questions about the sustainability of such valuations and the long-term viability of these business models. As more players enter the market, the challenge will be to differentiate their offerings and demonstrate tangible results.

Wang's departure from OpenAI highlights a broader trend in the tech industry, where talented researchers and engineers are increasingly moving towards entrepreneurship. The startup ecosystem has become more welcoming to young founders, as evidenced by the growing number of successful startups launched by individuals who may not have traditional credentials or extensive experience.

This shift is indicative of a changing mindset among investors, who are recognizing that innovation can come from unexpected places. The tech landscape is evolving rapidly, and the willingness to support young, ambitious entrepreneurs reflects a desire to tap into fresh ideas and disruptive technologies.

As Wang embarks on this new venture, he will likely face challenges common to startups, including building a strong team, securing funding, and navigating regulatory hurdles in the pharmaceutical industry. However, his background in AI research and the network he has developed at OpenAI may provide him with the necessary tools to succeed.

The implications of Wang's startup extend beyond the immediate business landscape. If successful, it could contribute to a paradigm shift in how drugs are discovered and developed, potentially leading to faster access to innovative treatments for patients. This could have a profound impact on public health, particularly in addressing unmet medical needs and improving patient outcomes.

In summary, Miles Wang's decision to leave OpenAI and launch an AI drug discovery startup reflects a significant trend within the tech and healthcare industries. As AI continues to reshape the landscape of drug development, the potential for breakthroughs in life sciences is immense. Investors are keenly interested in this space, and the successful application of AI in drug discovery could lead to transformative changes in how medications are developed and brought to market.